Dr Hui Wang (Hebei Yanda Ludaopei Hospital, China) explained the need for alternative gating panels for MRD detection by flow cytometry in B-ALL cases receiving CD19 CAR-T treatment [1]. To this end, Dr Wang and her team assessed MRD in the bone marrow of 59 patients by flow cytometry who had been treated with anti-CD19 CAR-T therapy bridging to allo-HSCT from June 2016 to March 2017. Instead of gating for CD19 in combination with the standard B-ALL markers (CD38/CD10/CD34/CD19/CD13+33/CD20/CD45 and CD81/CD34/cCD79a/CD10/CD45), the researchers investigated the prognostic value of gating for cCD79a in combination with a modified panel (CD38/CD10/CD34/CD19/cCD79a/CD20/CD45 and CD81/CD34/cCD79a/CD10/CD45).
To first validate the new panel against the old, 10 normal control bone marrow samples and 10 B-ALL MRD-positive samples were analysed in parallel. The new panel highly correlated with the standard panel, in normal control (R2=0.992), and MRD-positive (R2=0.9975) samples. The researchers then applied the new panel before and after treatment with CD19 CAR-T therapy for all 59 cases with cCD79a gating.
The results indicated that the new panel was prognostic of anti-CD19 CAR-T therapy bridging to allo-HSCT. Before CD19 CAR-T treatment, MRD varied between 0.48% and 93.28% (median 8.31%). Most patients (n=51) achieved MRD-negative complete remission (CR) after CAR-T therapy, and received allo-HSCT at a median of 64 days later. The 8 patients who were MRD-positive or relapsed after CAR-T therapy received allo-HSCT at a median of 31 days later.
With a median follow-up of 24 months after allo-HSCT, 42/51 cases (82.35%) achieved undetectable MRD. MRD was detected in 3/51 patients (5.88%) in the period of 90 to 450 days (median 120 days), and the remaining patients were lost to follow-up. Of the 8 patients who received allo-HSCT while being MRD-positive, 3 (37.5%) achieved MRD-negative CR status within in 24 months; 1 additional patient (12.5%) became MRD-negative CR in 5 months. The other 4 (50%) remained MRD-positive with 0.0031% to 1.93% detectable disease, of whom 2 died from relapse.
- Chen M, et al. Multicolor flow cytometry panel with CCD79A gating to detect minimal residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 CAR-T therapy bridging to allo-HSCT. EHA25 Virtual, 11-21 June 2020, Abstract S113.
Posted on
Previous Article
« Daratumumab for light-chain amyloidosis Next Article
Deep responses in R/R CLL with venetoclax monotherapy »
« Daratumumab for light-chain amyloidosis Next Article
Deep responses in R/R CLL with venetoclax monotherapy »
Table of Contents: EHA 2020
Featured articles
Myeloid
VIALE-A: newly diagnosed chemo-ineligible AML
DEC10-VEN superior to intensive chemotherapy in high-risk AML
Magrolimab plus azacitidine: good ORR in MDS/AML
Asciminib monotherapy in Ph+ CML: major molecular responses
CML TKI interruption: Swedish registry results
Patients with lower-risk MDS benefit from imetelstat
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
Lymphoid
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
Promising first-in-human trial of epcoritamab in B-NHL
Two trials: acalabrutinib in CLL
Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia
Deep responses in R/R CLL with venetoclax monotherapy
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging
Plasma Cell Dyscrasias
Daratumumab for light-chain amyloidosis
Isatuximab triplet improves PFS in R/R MM
Initial results from CAR-T cell therapy in MM: KarMMa
Graft-Versus-Host Disease
GRAVITAS-301: improved complete aGVDH response
Ruxolitinib improves steroid-refractory aGVHD across subtypes
Benign Haematology
Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan
Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results
SCD LentiGlobin gene therapy: new data on VOC and ACS
Paediatric Haematology
Venetoclax + navitoclax promising for R/R ALL or LL
Nivolumab/brentuximab vedotin in R/R HL: good CMR rates
Bench-to-Bedside Science from the Presidential Symposium
Microbiome predicts B-ALL predisposition
Netrin-1 regulates haematopoietic stem cells
Unrecognised role of iron in neutrophil differentiation
Related Articles
September 9, 2020
Asciminib monotherapy in Ph+ CML: major molecular responses
September 9, 2020
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
September 9, 2020
Magrolimab plus azacitidine: good ORR in MDS/AML
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com